Generics proposal pulled
This article was originally published in The Tan Sheet
FDA withdraws Aug. 6, 1999 proposed rule on 180-day generic exclusivity and ANDA approvals "in light of [court] decisions" invalidating agency's position on which rulings in patent infringement suits can trigger 180-day period. Proposal stated FDA would not start the clock until after a court decision from which no appeal could be taken, but a January 2000 D.C. federal court concluded 180 days was triggered by trial court decision on patent invalidity. Agency's most recent Hatch/Waxman proposed rule does not discuss the 180-day provision (1"The Tan Sheet" Oct. 28, 2002, p. 10). FDA will "carefully evaluate possible options for future rulemaking addressing 180-day exclusivity and the timing of ANDA approvals," agency says in 2Nov. 1 Federal Register notice...
You may also be interested in...
FDA's proposal to allow only one 30-month stay of approval for ANDAs hinges on a reinterpretation of Hatch/Waxman language declaring that patent holders must be notified if a generic application is amended to "include" a Paragraph IV certification
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.